Recombinant Mouse Carboxypeptidase B2 (Cpb2)

1. Results indicate that TAFIa could be a novel biomarker and realistic therapeutic target of chronic thromboembolic pulmonary hypertension. PMID: 28289017
2. Cpb2-deficient mice had decreased pneumococcal meningitis mortality and attenuated cytokine levels and bacterial outgrowth in the systemic compartment but not in the brain compartment, as compared with wild-type mice. PMID: 26340319
3. Carboxypeptidase B2 deficiency reveals that complement C3a limits infection and C5a exacerbates infection in a murine polymicrobial sepsis model. PMID: 25851247
4. Combination of TAFI-I and a low dose of rtPA was not as effective as the standard dose of rtPA in treating thromboembolic stroke, while TAFI inhibition alone was not effective at all. PMID: 25401979
5. In an induced osteoarthritis model, CPB2 knockout mice developed dramatically greater cartilage damage than did wild-type mice, had a greater number of osteophytes, and a greater degree of synovitis. PMID: 24449579
6. TAFI deficiency results in accelerated fibrogenesis and increased liver damage in murine models of chronic and acute liver disease, which may be related to increased inflammation. PMID: 23467679
7. The unique NFkappaB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFalpha. PMID: 22217421
8. These findings suggest that plasma carboxypeptidase B plays a critical role in dampening local, C5a-mediated inflammation and represents a molecular link between inflammation and coagulation in autoimmune arthritis. PMID: 21804193
9. In another mouse experiment, animals infected with isogenic Bacillus anthracis inhA deletion mutants restored TAFI levels, while the levels in the parent strain decreased. PMID: 21395696
10. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. PMID: 21724997
11. Apo-E deficiency alone is not associated with tumors but a lack of TAFI appears to make the mice permissive for tumor formation in ApoE mice PMID: 20723031
12. Study establishes the role of carboxypeptidase U in experimental abdominal aortic aneurysm disease, indicating that CPB has a broad anti-inflammatory role in vivo. PMID: 20431069
13. TAFI-deficient monocrotaline-treated mice had less pulmonary hypertension, vascular remodeling and reduced levels of cytokines possibly as a result of reduced coagulation activation. PMID: 20088932
14. role of pCPB as a modulator of the pivotal functions of plasminogen in fibrinolysis and cell migration in vivo. PMID: 12417566
15. there is a functional glucocorticoid response element (GRE) in the TAFI promoter which is capable of binding the glucocorticoid receptor PMID: 12645517
16. TAFI appears to be important for appropriate organization of the healing process PMID: 14521589
17. In all tumor models TAFI deficiency did not affect the formation and growth of primary and metastasized tumors. PMID: 15099284
18. thrombin-activable fibrinolysis inhibitor expression is enhanced by insulin through the PI3 kinase/Akt pathway PMID: 15647842
19. The anti-fibrinolytic activity of TAFI promotes lung fibrosis by hindering the rate at which fibrin is degraded. PMID: 16565485
20. beneficial effect of E229K thrombin is due to the direct inhibition of complement C5a by procarboxypeptidase B PMID: 17105819
21. data provide direct evidence for the role of TAFIa in vena cava thrombosis without the addition of exogenous thrombolytic in mice PMID: 17111204
22. increased renal activity of plasmin in TAFI-deficient mice causes increased renal interstitial fibrosis in obstructive nephropathy. PMID: 17988229
23. Suggest that TAFI-mediated inhibition of plasmin generation plays a role in the pathogenesis of glomerulonephritis. PMID: 18612543

Show More

Hide All

KEGG: mmu:56373

STRING: 10090.ENSMUSP00000022576

UniGene: Mm.24242